Literature DB >> 22760255

A case of successful preoperative chemotherapy with cisplatin and irinotecan followed by curative-intent surgery for locally advanced thymic carcinoma.

Shigeki Suzuki1, Hirotoshi Horio, Tai Hato, Masahiko Harada, Yusuke Okuma, Tsunekazu Hishima.   

Abstract

The optimal chemotherapy for thymic carcinoma has yet to be determined based on clinical evidence because of the rarity of this pathological entity. We report the case of a patient with locally advanced thymic carcinoma in whom radical excision was achieved with intensive preoperative chemotherapy followed by curative-intent surgery. A 59-year-old woman was diagnosed with Masaoka-Koga stage III thymic cancer showing squamous cell carcinoma histology. Invasion to the ascending aorta and left brachiocephalic vein was suspected from imaging, so preoperative chemotherapy with three cycles of cisplatin and irinotecan was administered. Partial response to chemotherapy was achieved and the residual tumor was completely resected with subsequent surgery. Histopathological examination of the resected specimen demonstrated stage II thymic carcinoma. The patient has shown no evidence of recurrence or surgical complications as of 46 months after completing preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760255     DOI: 10.1007/s11748-012-0123-2

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  10 in total

1.  Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

Authors:  Yusuke Okuma; Yukio Hosomi; Yusuke Takagi; Mari Iguchi; Tatsuru Okamura; Masahiko Shibuya
Journal:  Lung Cancer       Date:  2011-06-12       Impact factor: 5.705

2.  Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy).

Authors:  Thomonobu Koizumi; Yasuki Takabayashi; Satoshi Yamagishi; Kenji Tsushima; Akemi Takamizawa; Akihiro Tsukadaira; Hiroshi Yamamoto; Yoshitaka Yamazaki; Shinji Yamaguchi; Keisaku Fujimoto; Keishi Kubo; Yoshiki Hirose; Jirou Hirayama; Hisanori Saegusa
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

3.  Thymic carcinoma. Ten years' experience in twenty patients.

Authors:  C P Hsu; C Y Chen; C L Chen; C T Lin; N Y Hsu; J H Wang; P Y Wang
Journal:  J Thorac Cardiovasc Surg       Date:  1994-02       Impact factor: 5.209

4.  Thymic carcinomas: histopathological varieties and immunohistochemical study.

Authors:  T T Kuo; J P Chang; F J Lin; W C Wu; C H Chang
Journal:  Am J Surg Pathol       Date:  1990-01       Impact factor: 6.394

5.  Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.

Authors:  N Murray; A Shah; D Osoba; R Page; H Karsai; C Grafton; K Goddard; R Fairey; N Voss
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

6.  Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.

Authors:  Satoshi Igawa; Haruyasu Murakami; Toshiaki Takahashi; Yukiko Nakamura; Asuka Tsuya; Tateaki Naito; Kyoichi Kaira; Akira Ono; Takehito Shukuya; Akihiro Tamiya; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Lung Cancer       Date:  2009-05-05       Impact factor: 5.705

7.  Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.

Authors:  Kiyotaka Yoh; Koichi Goto; Gen-ichiro Ishii; Seiji Niho; Hironobu Ohmatsu; Kaoru Kubota; Ryutaro Kakinuma; Kanji Nagai; Moritaka Suga; Yutaka Nishiwaki
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

Review 8.  Thymic carcinoma: state of the art review.

Authors:  Tony Y Eng; Clifton D Fuller; Jaishree Jagirdar; Yadvindera Bains; Charles R Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-01       Impact factor: 7.038

9.  Squamous cell carcinoma of the thymus. An analysis of eight cases.

Authors:  Y Shimosato; T Kameya; K Nagai; K Suemasu
Journal:  Am J Surg Pathol       Date:  1977-06       Impact factor: 6.394

10.  Thymic carcinoma. A clinicopathologic study of 60 cases.

Authors:  S Suster; J Rosai
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.